Search Results

181 results

  1. CORESTA Meeting, Agronomy/Phytopathology, 2019, Victoria Falls, APPOST 10

    The influence of sodium carbonate buffer on TSNAs accumulation and leaf quality during tobacco storage

    LIU Xingyu(1); LIU Deshui(1); MA Li(1); MA Yanjun(1); YANG Zhendong(1); ZHANG Jie(1); LIN Lin(2); BAI Ruoshi(1); ZHOU Jun(1)
    (1) Technology Center, Shanghai Tobacco Group Co., Ltd., Beijing, P.R. China; (2) Beijing Tobacco Quality Supervision and Testing Station, Beijing, P.R. China
    Storage of tobacco leaves is an important stage in tobacco processing. Tobacco Specific N-nitrosamines (TSNAs) in tobacco leaves gradually increase during storage. The purpose of this study was to investigate the influence of sodium carbonate on the ...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 44

    Lung biomarkers of harm/effect for tobacco regulatory research: opportunities and challenges – a literature review

    MAKENA P.(1); EDMISTON J.(2); BEATTIE E.(3); MASON E.(4); McEWAN M.(5); PRASAD K.(5)
    (1) RAI Services Company, Winston-Salem, NC, U.S.A.; (2) Altria Client Services LLC, Richmond, VA, U.S.A.; (3) Cliantha Research Limited, Canada; (4) Imperial Brands PLC, Bristol, U.K.; (5) British American Tobacco (Investments) Limited, Southampton, U.K.
    Biomarkers of potential harm (BoPH) are indicators of biological perturbations in response to smoking, which may contribute to smoking-related disease. In this review, a project of the CORESTA Biomarkers Sub-Group, we critically assessed the available ...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 45

    Meta-analysis of two biomarkers of exposure of tobacco products

    AYALA-FIERRO F.(1); ELAMIN A.(2); FROST-PINEDA K.(3); JIN T.(3); PRASAD G.L.(3); SARKAR M.(4); SCHMIDT E.(3); VERRON T.(5)
    (1) ITG Brands LLC, Greensboro, NC, U.S.A.; (2) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (3) RAI Services Company, Winston-Salem, NC, U.S.A.; (4) Altria Client Services LLC, Richmond, VA, U.S.A.; (5) SEITA - Imperial Brands, Paris, France
    In the context of tobacco products, broadly two types of biomarkers exist, biomarkers of exposure (BoE) and biomarkers of potential harm (BoPH). BoE measure exposure to tobacco constituents, e.g. carbon monoxide (CO) and nicotine equivalents (NEQs). The ...
  4. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 42

    Characterization of whole mainstream smoke/aerosol delivery within the Vitrocell® Ames 48 high throughput exposure module using different tobacco product types

    LEVERETTE R.(1); KEYSER B.(1); SEYMOUR A.(2); HOLLINGS M.(2)
    (1) RAI Services Company, Scientific & Regulatory Affairs, Winston-Salem, NC, U.S.A.; (2) Covance Laboratories Ltd, Otley Road, Harrogate, North Yorkshire, U.K.
    The preferred means of assessing combustible or other aerosol-generating tobacco products in vitro is by direct exposure of cell cultures to freshly generated whole mainstream smoke/aerosols. This approach eliminates the fractionation of smoke/aerosols ...
  5. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 49

    The CORESTA in vitro test battery for combustible tobacco products: update from the 2004 Rationale and Strategy Report

    LEE K.M.(1); JORDAN K.G.(2); WIECZOREK R.(3); MOENNIKES O.(4); CLEMENTS J.(5); CROOKS I.(6); HASHIZUME T.(7); MILLER J.(8); WEBER E.(9); YOSHINO K.(7)
    (1) Altria Client Services, Richmond, VA, U.S.A.; (2) RAI Services Company, Winston-Salem, NC, U.S.A.; (3) Imperial Brands, Reemtsma Cigarettenfabriken GmbH, Hamburg, Germany; (4) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (5) Covance Laboratories Ltd, Harrogate, U.K.; (6) British American Tobacco (Investments) Ltd, R&D, Southampton, U.K.; (7) Japan Tobacco Inc., Yokohama, Kanagawa, Japan; (8) JT International SA, Geneva, Switzerland; (9) Ökolab, Vienna, Austria
    In 2004, the CORESTA In Vitro Toxicity Task Force issued a rationale and strategy report, commonly known as “the CORESTA in vitro test battery guideline”. The goals of this guideline were to: 1) develop the rationale and strategy for conducting in vitro ...
  6. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 50 (also presented at TSRC 2019)

    Altered lung barrier function is a physiologically-relevant biomarker of potential harm

    MAKENA P.; BAXTER-WRIGHT S.; CHEN P.; PRASAD G.L.
    RAI Services Company, Winston Salem, NC, U.S.A.
    Cigarette smoking is a major risk factor for diseases including cardiovascular disease, lung cancer, and chronic obstructive pulmonary disease (COPD). One of the key functions of lung epithelial cells is to serve as a physical barrier against insults ...
  7. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 51

    Structural investigation of the tobacco specific urinary biomarker iPX

    SCHMIDT E.; PRASAD G.L.
    RAI Services Company, Scientific & Regulatory Affairs, Winston-Salem, NC, U.S.A.
    Biomarkers of potential harm (BoPH) are tools to assess biological and pathophysiological effects associated with chronic tobacco product use, such as oxidative stress. Isoprostanes are widely recognized as BoPH for assessing endogenous oxidative stress. ...
  8. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 52 (also presented at TSRC 2019)

    A blood-based smoking-related gene expression signature using a machine learning approach

    LIU G.; PRASAD G.L.
    RAI Services Company, Winston-Salem, NC, U.S.A.
    Smoking is a leading risk factor in the onset of multiple forms of cancer, chronic obstructive pulmonary disease, and cardiovascular disease. At present, there is a limited understanding by which changes in gene expression profiles in blood or other ...
  9. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 58

    A consortium approach for consumer-reported outcome measures to assess tobacco- and nicotine-containing products

    ACQUADRO C.(1) on behalf of the CORESTA CROM Task Force: AYALA-FIERRO F.(2); BLACK R.(3); CAHOURS X.(4); CHREA C.(5); CURTIN G.(6); GILES L.(7); McCAFFREY S.(3); PARK C.H.(8); PRASAD K.(9); SHERWOOD N.(10); SHIFFMAN S.(11); SMITH J.(6); SPIES E.(5)
    (1) Mapi Research Trust, Lyon, France; (2) ITG Brands, Greensboro, NC, U.S.A.; (3) Altria Client Services, Richmond, VA, U.S.A.; (4) SEITA - Imperial Brands, Paris, France; (5) Philip Morris Products S.A., Neûchatel, Switzerland; (6) RAIS, Winston-Salem, NC, U.S.A.; (7) JT Int'l SA, Genève, Switzerland; (8) KT&G Research Institute, Daejeon, Republic of Korea; (9) British American Tobacco, Southampton, U.K.; (10) Neil Sherwood Consulting, Commugny, Switzerland; (11) Pinney Associates, Pittsburgh, PA, U.S.A.
    In the tobacco space, consumer-reported outcome measures (CROM) are essential for understanding motivations, subjective effects, and behavior. Such measures have become particularly important with the advent of candidate modified risk tobacco products ...